Synchron (@synchroninc) — Twitter Score 7 out of 1000

Synchron is a clinical-stage neurotechnology company co-founded by Thomas Oxley, Nicholas Opie, and Rahul Sharma to develop implantable brain-computer interfaces for people living with paralysis. Synchron's Twitter Score is 7.3 out of 1000 as of October 2026, ranking #123,193 among 497,973 tracked accounts.

Synchron's core product, Stentrode, is an endovascular device implanted through the jugular vein rather than through open-brain surgery, and is currently being assessed in clinical trials aimed at restoring communication and independence to paralyzed patients. In August 2025, Synchron announced the first thought-controlled iPad experience built on Apple's BCI Human Interface Device protocol, marking a significant milestone in consumer-device integration for BCI technology. Earlier that year, in March 2025, Synchron unveiled Chiral, which the company describes as a cognitive-AI brain foundation model, signaling a broader push into AI-driven neuroscience.

Synchron has also integrated a generative-AI chat feature powered by OpenAI into its BCI platform, and in November 2025 announced a $200 million Series D financing round. Backers include Khosla Ventures, ARCH Venture Partners, Gates Frontier, Bezos Expeditions, In-Q-Tel, Qatar Investment Authority, Greenoaks, Alumni Ventures, Protocol Labs, and others. Synchron has accumulated 6,894 followers as of October 2026 across 531 posts. Synchron has been mentioned by 17 accounts a total of 32 times.

Who follows Synchron on X?

The accounts that follow Synchron include 30 founders, 8 angel investors, 7 influencers and 1 VCs, among them Andrew Kang, Olaf, Riva, Juan Benet, Jerusalemware Corp and Alex Blania.